S&P ASX All Technology

US Dollar vs AUD

Register to chat with like-minded investors on our interactive forums.

Get Started

ALDX Aldeyra Therapeutics Inc

3.97

0.10 (2.58%)

18 Apr 2024 - Closed

Delayed by 15 minutes

Aldeyra says dry eye disease study for reproxalap did not meet main goal

To read the full story on Seeking Alpha, click here.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics Inc News

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Thursday 28 March 2024 (3 weeks ago) • Business Wire

Form S-3 - Registration statement under Securities Act of 1933
Friday 8 March 2024 (1 month ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 8 March 2024 (1 month ago) • Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Friday 8 March 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 8 March 2024 (1 month ago) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Tuesday 6 February 2024 (2 months ago) • Business Wire

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 4 January 2024 (3 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Thursday 4 January 2024 (3 months ago) • Business Wire

Form 8-K - Current report
Friday 22 December 2023 (4 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 19 December 2023 (4 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
Tuesday 19 December 2023 (4 months ago) • Business Wire

More Aldeyra Therapeutics Inc News Articles

Gold vs US Dollar

National Australia Bank

Commonwealth Bank Of Aus...

AUD vs US Dollar

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions